Phase 4
Completed N=76
Minimizing Pain During Office Intradetrussor Botox Injection
Overactive Bladder · Overactive Detrusor · Overactive Bladder Syndrome · Overactivity; Behavior
Source: ClinicalTrials.gov NCT04270526 ↗
Enrolled (actual)
76
Serious AEs
0.0%
Results posted
Mar 2025
Primary outcomePrimary: Pain: VAS — 25; 16 units on a scale, 0-100
◆ Published Evidence
Emerging
1citation · ~1 / year
A Randomized Controlled Trial of Instillation Protocols Prior to Intradetrusor OnabotulinumtoxinA.
Summary
This will be a prospective double-blinded randomized controlled trial comparing two pre-treatment protocols for patients undergoing intradetrussor botox injections to determine if a buffered lidocaine solution offers superior pain control.
Linked Publications
-
A Randomized Controlled Trial of Instillation Protocols Prior to Intradetrusor OnabotulinumtoxinA.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Pain: VAS |
25; 16 | — |
| SECONDARY Satisfaction: Likert Scale |
68; 39 | — |
| SECONDARY Willingness to Undergo Repeat Procedure |
72; 65 | — |
Eligibility Criteria
Inclusion Criteria
- Female patient
- Primary diagnosis of overactive bladder
- Failed first and second line therapy for overactive bladder
- Planning to undergo bladder botox injections
Exclusion Criteria
- Neurogenic bladder
- Urinary retention
Data sourced from ClinicalTrials.gov (NCT04270526) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.